Lataa...
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g. HER2-enriched disease) are more immunogenic than...
Tallennettuna:
| Julkaisussa: | J Immunother Cancer |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439986/ https://ncbi.nlm.nih.gov/pubmed/30922362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0548-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|